Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222098 · ClinicalTrials.gov registry record · Phase 1

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT07222098 is a Phase 1 study of Healthy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222098, a Phase 1 study of Healthy, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without calderasib

Conditions Studied

Interventions

  • DRUG Metformin
  • DRUG Calderasib
  • DRUG Rosuvastatin

Study Locations (1)

Nebraska

  • Celerion ( Site 0001) - Lincoln

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-11-19
Est. Completion 2025-12-23
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

What the Registry Record Tells You About NCT07222098

The ClinicalTrials.gov registry entry for NCT07222098 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.

NCT07222098 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT07222098 about?

NCT07222098 is a clinical study titled "A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)". Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without calderasib

What is the current status of trial NCT07222098?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-11-19. Estimated completion is 2025-12-23.

What conditions does trial NCT07222098 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07222098?

The interventions under investigation include: Metformin (DRUG), Calderasib (DRUG), Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT07222098?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222098 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.